Tanzania, Rwanda, and Zimbabwe Have Joined Recall of Johnson & Johnson Children’s Cough Syrup

Regulators in Tanzania, Rwanda, and Zimbabwe have joined Nigeria, Kenya, and South Africa in recalling a batch of Johnson & Johnson children’s cough syrup after tests revealed high levels of toxicity. The move comes as a precautionary measure to safeguard public health amid concerns over the presence of diethylene glycol, a toxic substance linked to fatal outcomes, particularly in children.

Diethylene glycol, found in the syrup, has been associated with severe health complications, including acute kidney failure. The recall follows laboratory tests conducted by Nigeria’s health regulator, which detected elevated levels of the harmful substance. The affected batch of Benylin Paediatric syrup was manufactured by Johnson & Johnson in South Africa in May 2021.

Also Read: Nigeria, Kenya and S.A Recalls Johnson & Johnson Children’s Cough Syrup Over Toxic Contamination

Tanzania’s Medicines and Medical Devices Authority initiated the recall on April 12 upon learning of the Nigerian test results. The spokesperson stressed that the recall was a precautionary measure aimed at removing the affected drugs from the market to prevent potential harm to consumers.

Kenya’s drug regulator is awaiting test results on the syrup, expected by Wednesday, to determine further actions. Rwanda’s Food and Drugs Authority issued a recall as a precautionary measure, despite not receiving reports of adverse events. Similarly, Zimbabwe’s Medicines Control Agency expressed concern about the potential illegal entry of the syrup into the local market and pledged to enhance inspections to prevent its distribution.

Kenvue, the current owner of the Benylin brand following a spin-off from Johnson & Johnson, stated that it is conducting its assessment and collaborating with health authorities to address the issue effectively.

The widening recall underscores the importance of stringent quality control measures in pharmaceutical products to ensure consumer safety. Regulators across Africa are taking proactive steps to mitigate risks associated with the consumption of contaminated medication, prioritising public health and well-being.